Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles

abstract (technical)
 

Highlights

•

Gene expression-driven scores predict platinum/taxane response

•

Association of proposed scores with HGSOC gene expression subtypes

•

Complimentary roles of platinum and taxane for personalized therapy

---

Objective

Prognoses of ovarian cancer (OC) have improved with the paclitaxel-carboplatin regimen. However, it remains unclear which cases exhibit a genuine benefit from taxane or from platinum. We aimed to predict taxane and platinum sensitivity in OC via gene expression.

Conclusions

Our proposal and finding of a scoring system that could predict platinum or taxane response could be useful to develop individualized treatments to ovarian cancer.